The United Kingdom and the United States have reached a important bilateral deal that will guarantee no levies on British drug products being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on pharmaceuticals through the National Health Service (NHS). This move guarantees that import taxes on these key goods will stay at nothing for a period of the next three years.
This development follows recent statements to dramatically increase import taxes on branded drug products, with increases floated reaching one hundred percent.
"This arrangement with the United Kingdom strengthens the worldwide climate for new treatments and establishes long-overdue balance to American-British drug exports," an announcement noted.
Trade Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest export categories to the America, which is by far the primary market for major UK drugmakers.
Export figures indicate that in the 12 months to the end of September, the UK exported medicines valued at £11.1bn to the US. This amount represented nearly one-fifth of all goods exports in that timeframe.
"This agreement safeguards employment, increases investment and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Detailed UK Commitments
The deal entails several key commitments from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to double total NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, repayments topped 20%.
Broader Context
This agreement comes amid a protracted row between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
This friction were intensified by assertions that US consumers were paying a premium for the equivalent treatments than people in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been delayed or cancelled, while major funding commitments have been directed toward US facilities.
A senior figure acknowledged that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
